- Home
- UCL vs MOLN Comparison
UCL vs MOLN Comparison
Compare UCL & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UCL
- MOLN
- Stock Information
- Founded
- UCL 2014
- MOLN 2004
- Country
- UCL Hong Kong
- MOLN Switzerland
- Employees
- UCL N/A
- MOLN N/A
- Industry
- UCL Telecommunications Equipment
- MOLN
- Sector
- UCL Consumer Discretionary
- MOLN
- Exchange
- UCL Nasdaq
- MOLN Nasdaq
- Market Cap
- UCL 144.5M
- MOLN 142.6M
- IPO Year
- UCL 2020
- MOLN 2021
- Fundamental
- Price
- UCL $3.91
- MOLN $3.47
- Analyst Decision
- UCL
- MOLN
- Analyst Count
- UCL 0
- MOLN 0
- Target Price
- UCL N/A
- MOLN N/A
- AVG Volume (30 Days)
- UCL 238.7K
- MOLN 1.1K
- Earning Date
- UCL 08-13-2025
- MOLN 08-25-2025
- Dividend Yield
- UCL N/A
- MOLN N/A
- EPS Growth
- UCL N/A
- MOLN N/A
- EPS
- UCL 0.02
- MOLN N/A
- Revenue
- UCL $89,277,000.00
- MOLN $2,525,030.00
- Revenue This Year
- UCL $6.09
- MOLN N/A
- Revenue Next Year
- UCL $7.01
- MOLN $1,000.00
- P/E Ratio
- UCL $169.37
- MOLN N/A
- Revenue Growth
- UCL 3.72
- MOLN N/A
- 52 Week Low
- UCL $0.80
- MOLN $3.36
- 52 Week High
- UCL $4.19
- MOLN $7.60
- Technical
- Relative Strength Index (RSI)
- UCL 74.41
- MOLN 43.67
- Support Level
- UCL $3.15
- MOLN $3.46
- Resistance Level
- UCL $4.10
- MOLN $3.68
- Average True Range (ATR)
- UCL 0.40
- MOLN 0.07
- MACD
- UCL 0.10
- MOLN -0.03
- Stochastic Oscillator
- UCL 85.03
- MOLN 10.91
About UCL uCloudlink Group Inc.
Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data related products to enable personal and enterprise users to access mobile internet in more than 100 countries and areas. Leveraging its inventive cloud SIM technology and architecture, the company redefine the mobile data connectivity experience, allowing users to gain access to mobile data traffic allowance shared by network operators on its marketplace. It has aggregated mobile data traffic allowances from 391 MNOs in 163 countries and regions in its cloud SIM architecture. The company derives maximum revenue from Japan.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.